SCHEMBL162148

SCHEMBL162148

O=C(O)CNC=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4968451 0.81 FAAH (0.37)
SCHEMBL8977177 0.78 MAOA (0.43)
SCHEMBL21723962 0.75 ALDH1A1 (0.43)
SCHEMBL25480 0.73
Hydrogen Peroxide SCHEMBL27648795 0.73
SCHEMBL165599 0.71
SCHEMBL1146702 0.71
SCHEMBL5706570 0.71
Water SCHEMBL1273106 0.71
Ammonia Solution, Strong SCHEMBL27190158 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1844 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
EP-4400164-A2 A METHOD OF INDUCING CARDIOMYOCYTES PROLIFERATION AND TREATING HEART DISEASES Yeda Research and Development Co. Ltd (IL) 2024-07-17 EP disclosed
US-20240190919-A1 PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME IMMUNITY PHARMA LTD. (IL) 2024-06-13 US disclosed
CN-118146196-A FAP inhibitors 海德堡大学 2024-06-07 CN disclosed
US-20240181020-A1 TREATMENT OF HYPOPARATHYROIDISM ENTERA BIO LTD. (IL) 2024-06-06 US disclosed
WO-2024118635-A2 THERMOSTABLE BINDING SCAFFOLDS NECTAGEN, INC. (US) 2024-06-06 WO disclosed
US-20240182532-A1 MICROPEPTIDES AND USES THEREOF FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) 2024-06-06 US disclosed
US-20240174730-A1 VARIANT FC DOMAINS AND USES THEREOF CIDARA THERAPEUTICS, INC. 2024-05-30 US disclosed
US-11986522-B2 Immunotherapeutic composition and uses thereof ARA VAX PTY LTD (AU) 2024-05-21 US disclosed
US-20240156975-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2024-05-16 US disclosed
WO-1997004091-A1 NOVEL RECEPTOR LIGANDS AND GENETIC SEQUENCES ENCODING SAME AMRAD OPERATIONS PTY. LTD. (AU) 1997-02-06 WO disclosed
EP-0745092-A1 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1996-12-04 EP disclosed
US-5480871-A TREATMENT OF BENIGN PROSTATIC HYPERPLASIA CHIRON CORPORATION (US) 1996-01-02 US disclosed
WO-1995027729-A1 OPIATE RECEPTOR LIGANDS CHIRON CORPORATION (US) 1995-10-19 WO disclosed
EP-0672049-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1995-09-20 EP disclosed
WO-1995004072-A1 PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS CHIRON CORPORATION (US) 1995-02-09 WO disclosed
WO-1994028014-A2 PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY CHIRON CORPORATION (US) 1994-12-08 WO disclosed
WO-1994011388-A1 SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS CHIRON MIMOTOPES PTY. LTD. (AU) 1994-05-26 WO disclosed
WO-1994003483-A1 ENDOTHELIN RECEPTOR-BINDING COMPOUNDS CHIRON CORPORATION (US) 1994-02-17 WO disclosed
US-4970214-A DIABETIC COMPLICATIONS NIPPON SHINYAKU CO., LTD. (JP) 1990-11-13 US disclosed